Study type: In vitro · Status: Evidence verified by machine against declared source
Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models.
ACS chemical neuroscience · 2022
Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Abstract only: Open source record
Product or molecular entity relationships
- Semax: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Public plain-language summary
Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Study design
It has previously been shown that Aβ1–42 oligomeric aggregates form insoluble amyloid deposits in the brain and hippocampus and exhibit neurotoxic effects in in vitro and in vivo models, leading to the cognitive dysfunction prevalent in the pathogenesis of AD.82,83 Thus, to assess the cytotoxicity of the oligomeric species, the effect of Aβ1–42 at different preparations of oligomerization on the viability of d-SH-SY5Y cells was investigated via an MTT assay (Figure 6).
Participants or experimental system
The principal hallmark of Alzheimer’s disease is the appearance in the hippocampal region of the brain4 of proteinaceous deposits inside neuronal cells, called neurofibrillary tangles, mainly constituted by fibrillar aggregates of phosphorylated tau protein,5 and in the extracellular space, called amyloid plaques, mainly constituted by fibrillar aggregates of amyloid beta protein (Aβ).6 Amyloid β protein is the final product of the aberrant cleavage of amyloid precursor protein (APP).7
Study scale
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Comparator
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Key findings
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.